The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
Open accessAbstract
UNLABELLED: Peptide receptor radionuclide therapy (PRRT) is a promising treatment for patients with neuroendocrine tumors, giving rise to improved survival. Dosimetric calculations in relation to PRRT have been concentrated to normal organ dosimetry in order to limit side effects. However, the relation between the absorbed dose to the tumor and treatment response has so far not been established. Better knowledge in this respect may improve the understanding of treatment effects, allow for improved selection of those patients who are expected to benefit from PRRT, and avoid unnecessary treatments. The aim of the present work was to evaluate the dose-response relationship for pancreatic neuroendocrine tumors treated with PRRT using (177)Lu-DOTATATE. METHODS: Tumor-absorbed dose calculations were performed for 24 lesions in 24 patients with metastasized pancreatic neuroendocrine tumors treated with repeated cycles of (177)Lu-DOTATATE at 8-wk intervals. The absorbed dose calculations relied on sequential SPECT/CT imaging at 24, 96, and 168 h after infusion of (177)Lu-DOTATATE. The unit density sphere model from OLINDA was used for absorbed dose calculations. The absorbed doses were corrected for partial-volume effect based on phantom measurements. On the basis of these results, only tumors larger than 2.2 cm in diameter at any time during the treatment were included for analysis. To further decrease the effect of partial-volume effect, a subgroup of tumors (>4.0 cm) was analyzed separately. Tumor response was evaluated by CT using Response Evaluation Criteria In Solid Tumors. RESULTS: Tumor-absorbed doses until best response ranged approximately from 10 to 340 Gy. A 2-parameter sigmoid fit was fitted to the data, and a significant correlation between the absorbed dose and tumor reduction was found, with a Pearson correlation coefficient (R(2)) of 0.64 for tumors larger than 2.2 cm and 0.91 for the subgroup of tumors larger than 4.0 cm. The largest tumor reduction was 57% after a total absorbed dose of 170 Gy. CONCLUSION: The results imply a significant correlation between absorbed dose and tumor reduction. However, further studies are necessary to address the large variations in response for similar absorbed doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cited by
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
Ljungberg, M., Celler, A., Konijnenberg, M. W., Eckerman, K. F., Dewaraja, Y. K., & Sjögreen-Gleisner, K. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.159012 · Cited by 369
Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations
Filosofov, D., Kurakina, E., & Radchenko, V. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.12.001 · Cited by 341
Garske-Román, U., Sandström, M., Fröss Baron, K., Lundin, L., Hellman, P., Welin, S., Johansson, S., Khan, T., Lundqvist, H., Eriksson, B., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3945-z · Cited by 254
Self-citationCremonesi, M., Ferrari, M. E., Bodei, L., Chiesa, C., Sarnelli, A., Garibaldi, C., Pacilio, M., Strigari, L., Summers, P. E., Orecchia, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4044-x · Cited by 141
Metadata
- Authors
- Ilan, E., Sandström, M., Wassberg, C., Sundin, A., Garske–Román, U., Eriksson, B., Granberg, D., & Lubberink, M.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2015-01-15
- Volume
- 56
- Issue
- 2
- Pages
- 177-182
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2099478219
- Cited by
- 227
- References
- 1
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE. https://app.cochat.ai/papers/10.2967/jnumed.114.148437
- The paper
- Ilan, E., Sandström, M., Wassberg, C., Sundin, A., Garske–Román, U., Eriksson, B., Granberg, D., & Lubberink, M. (2015). Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.114.148437
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.